PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

A strategy for combating drug-resistant cancers

2013-08-27
(Press-News.org) Many cancer therapies function by activating proteins like Caspase-3 (CASP3) that promote cell death. Several forms of cancer develop resistance to these drugs by down regulating CASP3 through an unknown mechanism. In the absence of CASP3, tumor cells produce another cell death promoting protein CASP7, but it is rendered inactive by the X-linked inhibitor of apoptosis protein (XIAP). In this issue of the Journal of Clinical Investigation, Po-Huang Liang and colleagues at Academia Sinica identify a compound (I-Lys) that disrupts the interaction between CASP7 and XIAP. Release of CASP7 from this complex in drug resistant cancer cells activated cell death and reduced malignancies. Furthermore, no adverse side effects were observed in non-tumor cells treated with the drug. In the accompanying commentary, Gregory Gores from the Mayo Clinic explains that these results are promising for combatting drug resistant cancers, but more work needs to be done to establish if I-Lys will be safe and beneficial for human use. ### TITLE: Targeting the XIAP/caspase-7 complex selectively kills caspase-3–deficient malignancies AUTHOR CONTACT: Po-Huang Liang
Academia Sinica, Taiwan R.O.C., Taipei, , TWN
Phone: +886-2-3366-4069; E-mail: phliang@gate.sinica.edu.tw View this article at: http://www.jci.org/articles/view/67951?key=e86860a6dfda17980263 ACCOMPANYING COMMENTARY TITLE: Unshackling caspase-7 for cancer therapy AUTHOR CONTACT: Gregory J Gores
Mayo Clinic, Rochester, MN, USA
Phone: 507-284-0686; Fax: 507-284-0762; E-mail: gores.gregory@mayo.edu View this article at: http://www.jci.org/articles/view/71440?key=31dca5188081bce3f0ca END


ELSE PRESS RELEASES FROM THIS DATE:

Protease inhibitor resistance involves multiple stages of the HIV-1 life cycle

2013-08-27
HIV-1 protease inhibitors are very effective antiviral drugs. These drugs target HIV-1 proteases, which are required for viral replication. Despite the success of protease inhibitors for suppressing HIV-1, some patients do not respond to protease inhibitor therapy. For most patients, the lack of response is not due to mutation of the HIV-1 protease. In this issue of the Journal of Clinical Investigation, Robert Silcano and colleagues at Johns Hopkins University identify the effects of protease inhibitors on different stages of viral replication. The authors found that protease ...

Origin of a hereditary east Texas bleeding disorder

2013-08-27
A severe hereditary bleeding disorder was described in a large family from east Texas in 2001. The affected family members routinely had bruising, nosebleeds, massive blood loss following injury or surgery, and often required blood transfusions. Routine tests for functional components of the blood coagulation pathway did not reveal any obvious defects. Genomic sequencing revealed a mutation in the gene encoding coagulation factor 5 (FV), but it was not considered to contribute to disease, since clotting assays were normal. In this issue of the Journal of Clinical Investigation, ...

Scientists prevent preterm birth caused by gene-environment interactions

2013-08-27
CINCINNATI – New research in the Journal of Clinical Investigation provides evidence that gene-environment interactions are a major contributor to preterm birth and that using a combinatory treatment strategy can prevent preterm delivery in a mouse model. In findings posted online Aug. 27, scientists from Cincinnati Children's Hospital Medical Center say their study provides important new insights into a major global health problem – one that remains stubbornly persistent in the United States. Preterm birth causes more than 1 million deaths a year and can leave premature ...

Study finds tumor suppressor may actually fuel aggressive leukemia

2013-08-27
CINCINNATI – New research in the Journal of Clinical Investigation suggests that blocking a protein normally credited with suppressing leukemia may be a promising therapeutic strategy for an aggressive form of the disease called acute myeloid leukemia (AML). Researchers from Cincinnati Children's Hospital Medical Center report their results in a study posted online Aug. 27 by the journal. The protein scientists targeted is a transcription factor known as RUNX1, which also plays an important role in helping regulate the normal development of blood cells. The researchers ...

Study identifies molecular process behind form of non-syndromic deafness

2013-08-27
CINCINNATI – Researchers identify an underlying molecular process that causes a genetic form of non-syndromic deafness in a new study that also suggests affected families may be at risk of damage to other organs. A multi-national research team led by scientists at Cincinnati Children's Hospital Medical Center report their findings in a study posted online Aug. 27 by the Journal of Clinical Investigation. The research opens the door to finding possible treatments for the condition (called DFNB49 non-syndromic hearing loss) and points to possible cellular damage in other ...

Personalized AF management needed to close mortality gap

2013-08-27
Amsterdam, The Netherlands – Tuesday 27 August 2013: Personalised management is the only way to close the mortality gap for patients with atrial fibrillation (AF), according to an ESC consensus paper presented at ESC Congress 2013 by Professor Paulus Kirchhof (UK). The Atrial Fibrillation competence NETwork (AFNET) and European Heart Rhythm Association (EHRA) consensus paper is published online in the European Journal of Pacing, Arrhythmias, and Cardiac Electrophysiology (EP-Europace)1 and presented during the ESC Congress session on personalised cardiology. Professor ...

A genetic treasure hunting in sorghum may benefit crop improvement

2013-08-27
August 27, 2013, Shenzhen, China - A consortium of researchers from The University of Queensland, the Queensland Department of Agriculture, Fisheries and Forestry (DAFF Qld) and BGI has discovered that sorghum, a drought-tolerant African crop, holds vastly more genetic variation than previously reported. This study published in Nature Communications today provides an invaluable resource for the genetic improvement of sorghum and other grass species. Sorghum is not only a food and feed cereal crop, but also can be used as the basis of biofuel. Its resistance to heat and ...

Novel approach to gene regulation can activate multiple genes simultaneously

2013-08-27
CAMBRIDGE, Mass. (August 27, 2013) – By creating a powerful new gene regulation system called CRISPR-on, Whitehead Institute researchers now have the ability to increase the expression of multiple genes simultaneously and precisely manipulate each gene's expression level. The system is effective in both mouse and human cells as well as in mouse embryos. "CRISPR-on is a tool that will be very useful for studying many biological processes, particularly for studying gene functions and gene networks," says Whitehead Founding Member Rudolf Jaenisch. "In contrast to RNA interference, ...

European hunter-gatherers owned pigs as early as 4600BC

2013-08-27
European hunter-gatherers acquired domesticated pigs from nearby farmers as early as 4600BC, according to new evidence. The international team of scientists, including researchers at Durham and Aberdeen universities, showed there was interaction between the hunter-gatherer and farming communities and a 'sharing' of animals and knowledge. The interaction between the two groups eventually led to the hunter-gatherers incorporating farming and breeding of livestock into their culture, say the scientists. The research, published in Nature Communications today (27 August), ...

Long-term memory in the cortex

2013-08-27
'Where' and 'how' memories are encoded in a nervous system is one of the most challenging questions in biological research. The formation and recall of associative memories is essential for an independent life. The hippocampus has long been considered a centre in the brain for the long-term storage of spatial associations. Now, Mazahir T. Hasan at the Max Planck Institute for Medical Research and José Maria Delgado-Garcìa at the University Pablo de Olavide of Seville, Spain, were able to provide first experimental evidence that a specific form of memory associations is ...

LAST 30 PRESS RELEASES:

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Higher blood pressure in childhood linked to earlier death from heart disease in adulthood

AI helped older adults report accurate blood pressure readings at home

High blood pressure in childhood and premature cardiovascular disease mortality

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital

New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment

New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment

Pennington Biomedical’s Dr. Steven Heymsfield named LSU Boyd Professor – LSU’s highest faculty honor

Study prompts new theory of human-machine communication

New method calculates rate of gene expression to understand cell fate

Researchers quantify rate of essential evolutionary process in the ocean

Innovation Crossroads companies join forces, awarded U.S. Air Force contract

Using new blood biomarkers, USC researchers find Alzheimer’s disease trial eligibility differs among various populations

Pioneering advances in in vivo CAR T cell production

Natural medicines target tumor vascular microenvironment to inhibit cancer growth

Coral-inspired pill offers a new window into the hidden world of the gut

nTIDE September2025 Jobs Report: Employment for people with disabilities surpasses prior high

When getting a job makes you go hungry

Good vibrations could revolutionize assisted reproductive technology

[Press-News.org] A strategy for combating drug-resistant cancers